Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Jonathan Rothberg
AddedMar 31, 2024
UpdatedJun 28, 2026
Jonathan Rothberg

Jonathan Rothberg

Board Member, 4Catalyzer

Crunchbase

Jonathan Rothberg's Career

4Catalyzer
4Catalyzer

Guilford, CT, US

Board Member· Board
Quantum-Si
Quantum-Si

Guilford, CT, US

Board Member· Board
Butterfly Network
Butterfly Network

Guilford, CT, US

Board Member· Board
Tesseract Health
Tesseract Health

Guilford, CT, US

Board Member· Board
AI Therapeutics
AI Therapeutics

Guilford, PA, US

Board Member· Board
Carnegie Mellon University
Carnegie Mellon University

Pittsburgh, PA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Jonathan Rothberg's Career

4Catalyzer
4Catalyzer
502014Guilford, CT, US
Board Member· Board
Quantum-Si
Quantum-Si
Public$425M1962013Guilford, CT, US
Board Member· Board

Recent news

Notion Capital raises $130M growth fund to tackle Europe’s follow-on gapTechCrunch · 2025
This founder left Silicon Valley to challenge US defense supremacy from Athens, and investors are paying attentionTechCrunch · 2025
Spotify’s Daniel Ek just bet bigger on Helsing, Europe’s defense tech darlingTechCrunch · 2025

Leadership at Quantum-Si

Jeff HawkinsJeff HawkinsBoard Member
Daniel FoxDaniel FoxCo-Founder

Similar to Quantum-Si

ErisyonErisyonAustin, TX, USProtein Sequencingest. 2018ErisyonAustin, TX, US · est. 2018

Erisyon, a pioneer in single molecule protein sequencing, revolutionizes disease detection and treatment.

Angel · $225k11
Glyphic BiotechnologiesGlyphic BiotechnologiesNew York City, NY, USProtein Sequencingest. 2021Glyphic BiotechnologiesNew York City, NY, US · est. 2021

Glyphic: A global consulting firm providing innovative business solutions with Fortune 1000 companies using top tech platforms.

Angel · $10.6M25
PhasiqPhasiqAnn Arbor, MI, USProtein Measurementest. 2012PhasiqAnn Arbor, MI, US · est. 2012

PHASIQ, a healthcare innovator since 2012, offers cost-effective, rapid, and precise health-indicator protein measurements.

Pre-Seed · $904.7k6
SeerSeerRedwood City, CA, USBiotech, Proteomicsest. 2017SeerRedwood City, CA, US · est. 2017

Proteomics tech firm pioneering in efficient nanoparticle-based workflows for large scale plasma and serum analysis.

Public · $169.5M164
Butterfly Network
Butterfly Network
Public$530M3302011Guilford, CT, US
Board Member· Board

Leadership at Butterfly Network

Nevada SanchezNevada SanchezCo-Founder
Tyler RalstonTyler RalstonCo-Founder
Louise PhanstielLouise PhanstielBoard Member
Joe DeVivoJoe DeVivoBoard Member

Similar to Butterfly Network

ExoExoRedwood City, CA, USMedical Imagingest. 2015ExoRedwood City, CA, US · est. 2015

Exo: Revolutionizing modern medicine with high-performance ultrasound imaging technology.

Series C · $307.6M233
Subtle MedicalSubtle MedicalMenlo Park, CA, USAI Software, Medical Imagingest. 2017Subtle MedicalMenlo Park, CA, US · est. 2017

Subtle Medical: Enhancing medical imaging efficiency and patient experience through innovative healthcare tech.

Seed · $49.2M77
PonsPonsJersey City, NJ, USMedical Imagingest. 2022PonsJersey City, NJ, US · est. 2022

AI-based medical tech firm offering mobile ultrasound solutions for remote imaging.

Pre-Seed · $405k6
True Digital SurgeryTrue Digital SurgeryGoleta, CA, USMedical Imagingest. 2018True Digital SurgeryGoleta, CA, US · est. 2018

True Digital Surgery offers a 3D medical imaging platform for enhanced surgical procedure visualization.

Series B · $31M125
Tesseract Health
Tesseract Health
Series B$80M452018Guilford, CT, US
Board Member· Board

Leadership at Tesseract Health

Vasiliki DemasVasiliki DemasCEO
Owen Kaye-KaudererOwen Kaye-KaudererCo-Founder
Jonathan RothbergJonathan RothbergCo-Founder
AI Therapeutics
AI Therapeutics
Public$98M172013Guilford, PA, US
Board Member· Board

Leadership at AI Therapeutics

Tian XuTian XuBoard Member
Brigette RobertsBrigette RobertsCEO

Similar to AI Therapeutics

Athos TherapeuticsAthos TherapeuticsTorrance, CA, USTherapeuticsest. 2019Athos TherapeuticsTorrance, CA, US · est. 2019

Athos Therapeutics: Pioneering AI-based precision treatments for autoimmune diseases and cancer.

Series A · $19.3M15
BioAI HealthBioAI HealthGoffstown, NH, USAI Diagnostics, Biotechest. 2020BioAI HealthGoffstown, NH, US · est. 2020

BioAI Health: Leveraging AI for improved disease diagnosis, therapy response prediction, and clinical trials.

Seed · $3M9
Alphina TherapeuticsAlphina TherapeuticsWestport, CT, USBiotechest. 2020Alphina TherapeuticsWestport, CT, US · est. 2020

Alphina Therapeutics: A biotech firm specializing in precision cancer medicine.

Series B · $16.9M8
Precision BiologicsPrecision BiologicsDallas, TX, USDiagnostics, Therapeuticsest. 2012Precision BiologicsDallas, TX, US · est. 2012

Precision Biologics, a Texas-based biotech firm, develops therapeutic and diagnostic products.

Series D · $59.4M11
Carnegie Mellon University
Carnegie Mellon University
Series A$472.6M11.4k1900Pittsburgh, PA, US
Board Member· Board

Recent news

Gather AI, maker of ‘curious’ warehouse drones, lands $40M led by Keith Block’s firmTechCrunch · 2026
Onepot AI raises $13M to help make chemical drug creation easierTechCrunch · 2025

Leadership at Carnegie Mellon University

J. Michael McQuadeJ. Michael McQuadeBoard Member
Ajit ShettyAjit ShettyBoard Member
Francisco D'SouzaFrancisco D'SouzaBoard Member
Yoshiaki FujimoriYoshiaki FujimoriBoard Member
Jeanne CunicelliJeanne CunicelliBoard Member
Tod JohnsonTod JohnsonBoard Member

Similar to Carnegie Mellon University

Case Western Reserve UniversityCase Western Reserve UniversityCleveland, OH, USEducation, Researchest. 1826Case Western Reserve UniversityCleveland, OH, US · est. 1826

CWRU: A renowned private research university, established in 1967 in Cleveland, Ohio.

Pre-Seed · $73.3M4.6k
Penn State UniversityPenn State UniversityUniversity Park, PA, USest. 1855Penn State UniversityUniversity Park, PA, US · est. 1855

Penn State: A renowned public, land-grant research university with multiple campuses across Pennsylvania.

Pre-Seed · $14.6M23.1k
Carnegie Mellon University College of Fine ArtsCarnegie Mellon University College of Fine ArtsPittsburgh, PA, USResearchest. 1905Carnegie Mellon University College of Fine ArtsPittsburgh, PA, US · est. 1905

Carnegie Mellon's College of Fine Arts: A global community cultivating renowned artists & professionals.

Series A · $10M3k
University of CincinnatiUniversity of CincinnatiCincinnati, OH, USResearchest. 1819University of CincinnatiCincinnati, OH, US · est. 1819

University of Cincinnati: Ohio's second largest public research university, founded in 1819.

Seed · $36.4M5.9k

Jonathan Rothberg's Similar Executives & Operators

Nugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to Jonathan Rothberg

Tillman GerngrossTillman GerngrossBoard Member · AlectorTyler JacksTyler JacksCo-Founder · T2 BiosystemsGerald FinkGerald FinkCo-Founder · BoragenCraig MelloCraig MelloCo-Founder · Phio PharmaceuticalsPamela SilverPamela SilverCo-Founder · 64x BioJay KeaslingJay KeaslingCo-Founder · Demetrix